ABL Texcell Diagnostics Reaches a New Strategic Milestone With a Proposed Acquisition of Vela Diagnostics' Activities in Singapore and the United States
The Company signs a non-binding letter of intent to acquire 100% of Vela Operations Singapore and Vela Diagnostics USA, with the ambition to consolidate an integrated international platform covering EMEA, Asia-Pacific and the United States
No change in control and governance of ABL Texcell Diagnostics or Advanced Biological Laboratories Luxembourg
WOIPPY, France, September 21, 2026--Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, announces that it has signed, alongside Advanced Biological Laboratories S.A. (ABL), its parent company, a non-binding letter of intent for a proposed acquisition of 100% of the share capital of Vela Operations Singapore Pte. Ltd. and Vela Diagnostics USA Inc.
The letter of intent was entered into between Advanced Biological Laboratories S.A., ABL Texcell Diagnostics S.A. and VDH Holding Pte. Ltd., the parent company of the Vela Group, acting as owner and assignor of the two companies involved.
A structuring project to accelerate international development
The proposed acquisition would be a new major step in ABL Texcell Diagnostics' development strategy.
Following the implementation of the exclusive distribution agreement for Vela Diagnostics' solutions in EMEA, the proposed acquisition would allow the Company to expand its operational and commercial footprint to two additional strategic territories: Asia-Pacific and the United States. The exclusive distribution agreement in EMEA had previously been presented as one of the structuring axes of the partnership between ABL Texcell Diagnostics and Vela Diagnostics.
The proposed combination would thus allow the Company to take a further step in its international change of scale and strengthen its position in the global market for molecular diagnostics for infectious diseases.
A non-binding letter of intent
The letter of intent sets out the general framework for discussions between the parties. It is non-binding regarding the completion of the proposed acquisition and does not create, at this stage, any obligation for the parties to complete the transaction, except for the stipulations expressly identified as binding.
The completion of the transaction remains subject to:
the satisfactory completion of due diligence work;
the negotiation and signing of final agreements;
the final determination of the scope of the operation;
the fulfilment of the usual prerequisites;
obtaining any social, regulatory or stock market authorizations that may be required.